Prevention of hypermagnesemia usually is possible. In mild cases, withdrawing magnesium supplementation is often sufficient. In more severe cases the following treatments are used:

- Intravenous calcium gluconate, because the actions of magnesium in neuromuscular and cardiac function are antagonized by calcium.

Definitive treatment of hypermagnesemia requires increasing renal magnesium excretion through:

- Intravenous diuretics, in the presence of normal kidney function

- Dialysis, when kidney function is impaired and the patient is symptomatic from hypermagnesemia

No treatment is generally required, as bone demineralisation and kidney stones are relatively uncommon in the condition.

Hypermagnesemia is an electrolyte disturbance in which there is a high level of magnesium in the blood. It is defined as a level greater than 1.1 mmol/L. Symptoms include weakness, confusion, decreased breathing rate, and cardiac arrest.

Hypermagnesemia can occur in kidney failure and those who are given magnesium salts or who take drugs that contain magnesium (e.g. some antacids and laxatives). It is usually concurrent with other electrolyte disturbances such as a low blood calcium and/or high blood potassium level. Specific electrocardiogram (ECG) changes may be present.

Treatment when levels are very high include calcium chloride, intravenous normal saline with furosemide, and hemodialysis.

Hypermagnesemia occurs rarely because the kidney is very effective in excreting excess magnesium.

As most cases of FHH are asymptomatic and benign, the diagnosis of FHH is less likely to be made.

Typically, diagnosis is made in the pursuit of uncovering the etiology of hypercalcemia.

Calcium levels are often in the high normal range or slightly elevated.

Commonly, the parathyroid hormone level is checked and may be slightly elevated or also on the high normal end.

Normally, high calcium should cause low PTH and so this level of PTH is inappropriately high due to the decreased sensitivity of the parathyroid to calcium.

This may be mistaken for primary hyperparathyroidism.

However, evaluation of urine calcium level will reveal a low level of urine calcium.

This too is inappropriate as high serum calcium should result in high urine calcium.

If urine calcium is not checked, this may lead to parathyroidectomy for presumed primary hyperparathyroidism.

Additionally as the name implies, there may be a family history of benign hypercalcemia.

Ultimately, diagnosis of familial hypocalciuric hypercalcemia is made — as the name implies — by the combination of low urine calcium and high serum calcium.

Medications offered can include the immunosuppressant prednisone, intravenous gamma globulin (IVIG), anticonvulsants such as gabapentin or Gabitril and antiviral medication, depending on the underlying cause..

In addition to treatment of the underlying disorder, palliative care can include the use of topical numbing creams, such as lidocaine or prilocaine. Care must be taken to apply only the necessary amount, as excess can contribute to the condition. Otherwise, these products offer extremely effective, but short-lasting, relief from the condition.

Paresthesia caused by stroke may receive some temporary benefit from high doses of Baclofen multiple times a day. HIV patients who self-medicate with cannabis report that it reduces their symptoms.

Paresthesia caused by shingles is treated with appropriate antiviral medication.

Neuromuscular junction disease is a medical condition where the normal conduction through the neuromuscular junction fails to function correctly.

In diseases such as myasthenia gravis, the end plate potential (EPP) fails to effectively activate the muscle fiber due to an autoimmune reaction against acetylcholine receptors, resulting in muscle weakness and fatigue.

Myasthenia gravis is caused most commonly by auto-antibodies against the acetylcholine receptor. It has recently been realized that a second category of gravis is due to auto-antibodies against MuSK. A different condition, Lambert-Eaton myasthenic syndrome, is usually associated with "presynaptic" antibodies to the voltage-dependent calcium channel. It is possible for these conditions to coexist.

The treatment of psychosis depends on the specific diagnosis (such as schizophrenia, bipolar disorder or substance intoxication). The first-line psychiatric treatment for many psychotic disorders is antipsychotic medication, which can reduce the positive symptoms of psychosis in about 7 to 14 days.

The choice of which antipsychotic to use is based on benefits, risks, and costs. It is debatable whether, as a class, typical or atypical antipsychotics are better. Tentative evidence supports that amisulpride, olanzapine, risperidone and clozapine may be more effective for positive symptoms but result in more side effects. Typical antipsychotics have equal drop-out and symptom relapse rates to atypicals when used at low to moderate dosages. There is a good response in 40–50%, a partial response in 30–40%, and treatment resistance (failure of symptoms to respond satisfactorily after six weeks to two or three different antipsychotics) in 20% of people. Clozapine is an effective treatment for those who respond poorly to other drugs ("treatment-resistant" or "refractory" schizophrenia), but it has the potentially serious side effect of agranulocytosis (lowered white blood cell count) in less than 4% of people.

Most people on antipsychotics get side effects. People on typical antipsychotics tend to have a higher rate of extrapyramidal side effects while some atypicals are associated with considerable weight gain, diabetes and risk of metabolic syndrome; this is most pronounced with olanzapine, while risperidone and quetiapine are also associated with weight gain. Risperidone has a similar rate of extrapyramidal symptoms to haloperidol.

Psychological treatments such as acceptance and commitment therapy (ACT) are possibly useful in the treatment of psychosis, helping people to focus more on what they can do in terms of valued life directions despite challenging symptomology.

Other causes may include:

- Anticonvulsant pharmaceutical drugs, such as topiramate, sultiame, and acetazolamide

- Anxiety and/or panic disorder

- Benzodiazepine withdrawal syndrome

- Beta alanine

- Carpal tunnel syndrome

- Cerebral amyloid angiopathy

- Chiari malformation

- Coeliac disease (celiac disease)

- Complex regional pain syndrome

- Decompression sickness

- Dehydration

- Dextromethorphan (recreational use)

- Fabry disease

- Erythromelalgia

- Fibromyalgia

- Fluoroquinolone toxicity

- Guillain–Barré syndrome (GBS)

- Heavy metals

- Herpes zoster

- Hydroxy alpha sanshool, a component of Sichuan peppers

- Hyperglycemia (high blood sugar)

- Hyperkalemia

- Hyperventilation

- Hypoglycemia (low blood sugar)

- Hypocalcemia, and in turn:

- Hypermagnesemia, a condition in which hypocalcemia itself is typically observed as a secondary symptom

- Hypomagnesemia, often as a result of long term proton-pump inhibitor use

- Hypothyroidism

- Immunodeficiency, such as chronic inflammatory demyelinating polyneuropathy (CIDP)

- Intravenous administering of strong pharmaceutical drugs acting on the central nervous system (CNS), mainly opioids, opiates, narcotics; especially in non-medical use (drug abuse)

- Ketorolac

- Lidocaine poisoning

- Lomotil

- Lupus erythematosus

- Lyme disease

- Menopause

- Mercury poisoning

- Migraines

- Multiple sclerosis

- Nitrous oxide, long-term exposure

- Obdormition

- Pyrethrum and pyrethroid (pesticide)

- Rabies

- Radiation poisoning

- Sarcoidosis

- Scorpion stings

- Spinal disc herniation or injury

- Spinal stenosis

- Stinging nettles

- Syringomyelia

- Transverse myelitis

- Vitamin B deficiency

- Vitamin B deficiency

- Withdrawal from certain selective serotonin reuptake inhibitors (or serotonin-specific reuptake inhibitors) (SSRIs), such as paroxetine or serotonin-norepinephrine reuptake inhibitors (SNRIs) such as venlafaxine